Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer

Phase 3Active Not RecruitingNCT06709144

Haixing Ju, MD896 enrolled

Overview

The study was conducted on patients with advanced right-sided colon cancer, and the clinical pathological and prognostic data of the patients were compared between the two groups of patients who were randomly divided into those undergoing SMV and SMA left resection, with the aim of resolving the controversy over the left resection boundary of CME/D3 lymph node dissection through this study, and to clarify whether SMA left resection is superior to SMV left resection.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

896

Conditions

Colon Cancer

Interventions

SMA lymph node dissectionPROCEDURE

The lymph node dissection boundary is on the left side of the superior mesenteric artery (SMA)

SMV lymph node dissectionPROCEDURE

The lymph node dissection boundary is on the left side of the superior mesenteric vein (SMV)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 78 Years

Medical Language ↔ Plain English

Inclusion Criteria: * right side colon cancer(The primary lesion is located in the ileocecal region, ascending colon, hepatic flexure of colon, or proximal transverse colon) * T3-4 and/or N1-2M0 * Colonoscopy and pathological biopsy confirmed colon adenocarcinoma Exclusion Criteria: * T1-2N0M0 * Cannot undergo curative resection * Simultaneous multiple primary colorectal cancer or other diseases requiring segmental resection * Distant metastasis * Tumor invades surrounding organs, requiring joint organ resection * Emergency surgery is required for complications such as intestinal obstruction, perforation, and bleeding * Patients who have received neoadjuvant therapy before surgery * Pregnant or lactating women * Patients who are not suitable or unable to tolerate surgery

Locations (1)

Zhejiang cancer hospital

Hangzhou, Zhejiang, China

Outcomes

Primary Outcomes

3 year DFS

3 year disease free survival

Time frame: 3 years

Secondary Outcomes

5 year OS

5 year Overall survival

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.